Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Seattle Genetics Inc

+ Add to Watchlist

SGEN:US

35.3500 USD 0.7500 2.08%

As of 20:10:00 ET on 03/31/2015.

Snapshot for Seattle Genetics Inc (SGEN)

Open: 36.0900 Day's Range: 35.1600 - 36.2900 Volume: 675,583
Previous Close: 36.1000 52wk Range: 30.0500 - 47.6700 1-Yr Rtn: -24.45%

Stock Chart for SGEN

No chart data available.
  • SGEN:US 35.3500
  • 1D
  • 1M
  • 1Y
36.1000
Interactive SGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SGEN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.6200
Est. EPS (USD) (12/2015) -0.7270
Est. PEG Ratio -
Market Cap (M USD) 4,394.67
Shares Outstanding (M) 124.32
30 Day Average Volume 1,214,955
Price/Book (mrq) 20.7862
Price/Sale (ttm) 15.2144
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for SGEN

Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company's technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer.

Clay B SiegallChairman/Pres/CEO/Co-FounderTodd E SimpsonChief Financial Officer
Eric L DobmeierCOO/SecretaryJean I LiuExec VP:Legal Affairs/Gen Counsel/Secy
More Company Profile & Key Executives for SGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil